<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5429">
  <stage>Registered</stage>
  <submitdate>13/09/2005</submitdate>
  <approvaldate>13/09/2005</approvaldate>
  <nctid>NCT00182403</nctid>
  <trial_identification>
    <studytitle>Fixed Dose Heparin Study</studytitle>
    <scientifictitle>Fixed Dose Unfractionated Heparin for Initial Treatment of Venous Thromboembolism</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>#NA3640</secondaryid>
    <secondaryid>CTMG-2005-FIDO</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Venous Thromboembolism</healthcondition>
    <healthcondition>Deep Vein Thrombosis</healthcondition>
    <healthcondition>Pulmonary Embolism</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Other cardiovascular diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Blood </conditioncode1>
      <conditioncode2>Clotting disorders</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Other respiratory disorders / diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - UFH 250 U/kg or LMWH 100 U/kg sc twice daily

Treatment: drugs: UFH 250 U/kg or LMWH 100 U/kg sc twice daily


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Symptomatic Venous Thromboembolism</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Major Bleeding</outcome>
      <timepoint />
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Death</outcome>
      <timepoint />
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>aXa ~6h after sc injection on 3rd day of treatment</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  A diagnosis of acute venous thromboembolism (VTE,DVT and /or PE)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Contraindication to subcutaneous (sc) route of administration (eg:shock (evidence of
             poor peripheral perfusion), major surgery within 48 hours)

          -  Active Bleeding process

          -  Comorbid condition limiting expected survival to less than 3 months

          -  Current treatment with therapeutic dose of UFH, LMWH, danaparoid sodium, or a direct
             thrombin inhibitor for more than 48 hours

          -  Currently on long term warfarin or heparin therapy

          -  Allergy to heparin or history of heparin induced thrombocytopenia

          -  Currently pregnant

          -  Contraindication to contrast media (eg: allergy or creatinine &gt;200 umol/L).

          -  Currently enrolled or will be enrolled in a competing study

          -  Geographically inaccessible for follow-up assessment</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/09/1998</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize />
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Ontario</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otahuhu</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>McMaster University</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Heart and Stroke Foundation of Ontario</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>FIDO was a multicentred randomized, open-label trial that compared fixed-dose UFH with
      fixed-dose LMWH for initial treatment of VTE. Patients were followed for 3 months during
      which they received warfarin (target INR 2.0-3.0).</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00182403</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Clive Kearon, MB Ph.D</name>
      <address>Hamiton Health Sciences</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>